Mitochondria-Targeted Iron Chelator Offers Photoprotection

This article originally appeared here.
Share this content:
Mitochondria-Targeted Iron Chelator Offers Photoprotection
Mitochondria-Targeted Iron Chelator Offers Photoprotection

FRIDAY, July 29, 2016 (HealthDay News) -- A mitochondria-targeted iron chelator can protect primary skin fibroblasts against the harmful effects of ultraviolet A (UVA), according to a study published in the August issue of the Journal of Investigative Dermatology.

Olivier Reelfs, Ph.D., from the University of Bath in the United Kingdom, and colleagues designed a mitochondria-targeted hexadentate iron chelator linked to mitochondria-homing SS-like peptides. They evaluated the photoprotective potential of this compound against UVA-induced oxidative damage and cell death in cultured primary skin fibroblasts.

The researchers found that the compound provided protection against UVA-induced mitochondrial damage, depletion of adenosine triphosphate, and the ensuing necrotic cell death. This effect was fully related to the iron-chelating property in the mitochondria.

"This mitochondria-targeted iron chelator has therefore promising potential for skin photoprotection against the deleterious effects of the UVA component of sunlight," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Post-Deployment Screening Has Limited Benefit in U.K. Military

Post-Deployment Screening Has Limited Benefit in U.K. Military

Screening based on tailored advice does not reduce prevalence of disorders or increase help-seeking

Excess BMI Ups Risk of T1DM in Autoantibody-Positive Relatives

Excess BMI Ups Risk of T1DM in Autoantibody-Positive ...

Increased diabetes progression risk occurred at lower cumulative excess BMI index in children <12

Baricitinib Associated With Significant Improvement in RA

Baricitinib Associated With Significant Improvement in RA

Findings versus placebo, adalimumab in patients non-responsive to methotrexate

is free, fast, and customized just for you!

Already a member?

Sign In Now »